GlassScriptPhysician profile
Tibebu T Tefera
NPI 1801025788
$1,371.07
in general payments reported to CMS, 2019-2025
22 companies · $87.61 in 2025
The $87.61 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $124 · 2021: $145 · 2022: $288 · 2023: $168 · 2024: $202 · 2025: $87.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $382.14 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $171.18 | 2019-2024 | |
| Genzyme Corporation | $91.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.23 | 2022-2023 | Jardiance |
| Abbvie INC. | $72.02 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.53 | 2019-2024 | Xifaxan |
| Inari Medical, INC. | $61.52 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $58.83 | 2021-2022 | |
| Novo Nordisk INC | $49.48 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $48.31 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $45.29 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.52 | 2020-2022 | |
| Gilead Sciences, INC. | $20.85 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.82 | 2019 | |
| Cvrx, INC. | $19.55 | 2025 | Barostim Neo System |
| Stryker Corporation | $18.71 | 2025 | Ivas |
| Melinta Therapeutics, LLC | $17.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.80 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.39 | 2023 | Lifevest |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tibebu Tefera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.